Skip to main content
Caplight Logo









Genes2Me

Genes2Me

Private
IndiaHealthcare & Life Scienceshttps://genes2me.com/

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Genes2Me is a biotechnology, genetics, and health care company that develops and manufactures in-vitro diagnostic (IVD) solutions, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, and RT-PCR kits.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

molecular diagnosticsin-vitro diagnosticsIVDgenetic testingdiagnostic manufacturingRT-PCR kitspoint-of-care testingPOC testingrapid diagnostic testsnext-generation sequencingNGS assaysDNA testingliquid biopsyNIPToncology diagnosticsnucleic acid extractioninfectious disease testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genes2Me Comparables

Compare Genes2Me with similar companies based on industry and business-model similarity.

Genes2Me comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mylab Discovery Solutions
86%
NeoDx Biotech Labs
81%
GenePath Diagnostics
80%

Genes2Me Funding Rounds

Historical fundraising activity

View Full Funding History

Access detailed round history, amounts raised, valuations, and investors.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 22, 2026

    Open roles increased to 27, representing 24% of headcount.

  • May 17, 2026

    Monthly visitors increased 44% MoM, from 3.9K to 5.7K.

Recent news

Latest coverage and updates

  • launchesJul 25, 2026

    Genes2Me Private Limited launches CliSeq Interpreter.

  • launchesJul 16, 2026

    Genes2Me Private Limited launches RT-PCR portfolio.

  • launchesJul 2, 2026

    Genes2Me Pvt. Ltd. launches targeted TB NGS assay.

Genes2Me Filings

Explore SEC and related filing metadata, where available.

Genes2Me filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Genes2Me's valuation, stock price, and market status.

Is Genes2Me a public or private company?

Genes2Me is a private company.

What is the current stock price of Genes2Me?

Genes2Me is a private company with no public stock price. No recent secondary market data is available.

How much is Genes2Me worth (valuation)?

Valuation information for Genes2Me is not publicly available.

Can I buy Genes2Me stock?

Genes2Me shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Genes2Me's last funding round?

Funding round information for Genes2Me is not publicly available.

Who are the main investors in Genes2Me?

Investor information for Genes2Me is not publicly disclosed.

Will Genes2Me IPO soon?

No public IPO plans have been announced for Genes2Me.

How can I track Genes2Me secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Genes2Me's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIndia
Employee Range115
Year Founded2016
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?